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ABSTRACT 
 
 In bottom-up mass spectrometry-based proteomics analyses, variability at 
any step of the process, particularly during sample proteolysis, directly affects the 
sensitivity, accuracy and precision of peptide detection and quantification. 
Currently, no generic internal standards are available to control the quality of 
sample processing steps. This makes it difficult to assess the comparability of 
MS proteomic data obtained in different experimental conditions. Here, we 
describe the design, synthesis and validation of a universal protein standard, 
called DIGESTIF, that can be added to any biological sample. The DIGESTIF 
standard consists of a soluble recombinant protein scaffold to which a set of 11 
artificial peptides (iRT peptides) with good ionization properties has been 
incorporated. In the protein scaffold, the amino acids flanking iRT peptide 
cleavage sites were selected to either favor or hinder protease cleavage. After 
sample processing, the retention time and relative intensity pattern of the 
released iRT peptides can be used to assess the quality of sample workup, the 
extent of digestion and the performance of the LC-MS system. Thus, DIGESTIF 
can be used to standardize a broad spectrum of applications, ranging from 
simple replicate measurements up to large-scale biomarker screenings in 
biomedical applications. 
 
 
KEYWORDS: Proteolysis, digestion, standard, proteomics, mass spectrometry, 
biomarkers. 
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ABBREVIATIONS 
 
CE: Collision Energy 
iRT peptide: indexed Retention Time peptide 
PSAQ: Protein Standard Absolute Quantification 
QconCAT: Quantification Concatemer 
RT: Retention Time 
SRM: Selected Reaction Monitoring, also referred to as MRM (Multiple Reaction 
Monitoring) 
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INTRODUCTION 
 
 Over the last two decades, extensive technological and methodological 
advances have led to the widespread use of mass spectrometry (MS)-based 
bottom-up proteomics. MS-based analysis is the method of choice for large-scale 
exploration of proteomes in biological systems and has significantly contributed 
to the comprehension of a variety of biological processes 1. In the field of medical 
diagnostics, quantitative MS has been an integral part of numerous biomarker 
discovery and evaluation studies 2,3. The rapid growth of therapeutic classes 
employing protein-based compounds, in particular monoclonal antibodies, has 
led to the implementation of MS at all stages in their development for structural 
and analytical characterization 4. 
 Bottom-up proteomics - which involves the digestion of proteins into 
peptides followed by identification and quantification of the resulting peptides by 
LC-MS - remains the method of choice for proteome characterization and 
quantification 5,6 in spite of impressive advances in top-down proteomics 7 and 
affinity-based proteomic measurements 8. Because of this, elaborate multistep 
protocols have been established to support the application of bottom-up 
proteomics even for complex samples. These protocols typically include the 
extraction of proteins from tissues, cells or body fluids; proteins are then cleaved 
and the resulting peptide mixtures are separated on a reversed-phase column 
prior to MS analysis. To achieve high quality and highly reproducible results, all 
steps in this complex procedure must be carefully validated and controlled. To 
date, attempts to standardize the complex workflow have been moderately 
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successful 9 mainly because of the stochastic steps involved 10-13. Because of 
these steps, quality control and assessment efforts in bottom-up proteomics have 
tended to focus on the use of various reference standards to check performance 
at specific stages in the process. Thus, specific studies have been conducted 
with different types of standards to monitor LC separation, to optimize mass 
spectrometer performance 14, to assess protein digestion 15,16 or to evaluate the 
reproducibility of measurements 12,17,18. 
 In an attempt to expand on these, Eyers and coworkers 19 presented 
QCAL, a recombinant protein standard consisting of a set of concatenated 
peptides, in 2008. After trypsin digestion, QCAL provides a stoichiometrically 
controlled peptide mixture allowing the concomitant assessment and optimization 
of multiple MS-instrument parameters on a wide variety of instrument platforms.  
More recently, Escher and coworkers 20 described a method to 
standardize chromatographic retention time as an iRT (indexed retention time) 
using a set of standard peptides (iRT peptides). These peptides are now 
commercially available as a kit. The iRT method was designed to precisely 
identify and correct for variations in retention time across a series of LC-MS 
measurements. This is particularly relevant for LC-SRM analyses. The iRT 
peptide set consists of 11 artificial peptide standards of varying hydrophobicity; 
these peptides are eluted at regular intervals from classical C18 reverse-phase 
columns using standard LC gradients. When spiked into the biological matrix to 
be studied, they serve as standards and make it possible to accurately predict 
the retention time of peptides monitored in LC-MS experiments. By monitoring 
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peptide precursors and defined SRM transitions, the iRT peptide signals also 
give indications on the performance of the MS system and provide a backdrop for 
statistical target validation and reproducible protein quantification in SRM assays, 
using the mProphet or Skyline softwares 21,22. While undoubtedly a very useful 
tool, the iRT peptides are spiked into samples post-digestion, they therefore 
cannot be used to monitor sample preparation variance.  
These sample processing steps are crucial, particularly for quantitative 
proteomics applications in clinical settings. It is therefore necessary to be able to 
rigorously evaluate and benchmark them. To meet this need, Percy and 
colleagues 23 recently described two sets of reagents to specifically help with 
standardization of biomarker detection in human plasma samples. The first set 
(“LC-MS test kit”) is designed to check LC-MS performance. It contains plasma 
digests spiked with labeled peptides representing 43 high-to-moderate 
abundance plasma proteins. The second set (“QC test kit”) is used to evaluate 
the entire analytical workflow (including proteolysis). It is composed of plasma 
samples, trypsin and the mix of 43 surrogate labeled peptides. Using these two 
kits, the reproducibility and reliability of quantitative biomarker analyses across 
laboratories can be enhanced. They also pave the way for benchmarking 
proteomics-based biomarker detection in human plasma for diagnostic 
applications. However, it is important to note that the reagents contained in these 
kits have been specifically optimized for use with plasma, which is the most 
complex and widely used human protein sample. Thus, they may not be suitable 
for use with other sample types, and it might be necessary, for each sample 
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and/or proteomics workflow, to compile a distinct set of test- and quality control 
reagents. 
 Although these solutions have significantly improved standardization of 
bottom-up proteomics experiments, the major source of variation affecting protein 
sequence coverage, detection sensitivity and, in particular, protein quantification 
remains proteolysis 16,24-31. In bottom-up proteomics experiments, the most 
commonly used protease is trypsin. The rules for trypsin specificity (also referred 
to as “Keil rules”) were initially defined in 1992 as "C-terminal cleavage to 
arginine and lysine but not, or at very low-frequency, before proline" 32. These 
rules were experimentally validated in 2004 on a large LC-MS/MS data set 
corresponding to the mouse liver proteome 33. Then, using 14.5 million LC-
MS/MS spectra from Shewanella oeidensis, Rodriguez and co-workers 34 further 
refined these rules. These authors identified amino acids flanking cleavage sites 
and strongly influencing digestion efficiency. These data were further confirmed 
by subsequent studies using different datasets 28,35. 
 In addition to the effects of surrounding sequences and protein structure, 
proteolytic cleavage of target proteins may be altered in a variety of body fluids or 
tissue samples. To assess this, various monitoring concepts have been 
developed. In 2005, Cutillas and coworkers 36 described the use of fetuin as an 
internal standard to control in-gel digestion. Their results were promising, but 
unfortunately this standard was not assessed in other proteolysis conditions. 
Additionally, as fetuin is a plasma protein, it is not suited to the study of plasma 
or serum samples. In 2012, Burkhart and coworkers proposed the use of a 
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monolithic column HPLC setup with UV detector to evaluate digestion efficiency 
and reproducibility prior to LC-MS/MS analysis16. An alternative approach is to 
spike samples with isotopically labeled standards before protein digestion. The 
best-known examples of these are Quantification Concatamers (QconCATs) and 
Protein Standards for Absolute Quantification (PSAQ™ standards) 37,38. Both of 
these standards have mainly been used for the absolute quantification of specific 
target proteins in a mixture, based on the assumption that the external reference 
molecule and the endogenous counterpart share a similar fate during proteolysis 
and sample work-up. This assumption is more likely to be true for PSAQ 
standards than for QconCATs, as the peptides released from the QconCAT are 
not in the same sequence context as peptides released from the endogenous 
proteins 39. This can be problematic as complex protein mixtures not only consist 
of proteins that are easily cleaved, but also contain highly structured species that 
may, in part, resist efficient proteolysis. QconCATs (including QCAL) are not 
predicted to form significant regions of secondary structure. In fact, they are 
designed and optimized for the most efficient release of their surrogate peptides 
24,39
. While this may be appropriate for the specifically targeted proteins, it means 
they are poorly suited for evaluation of the digestion efficiency in complex 
mixtures. Similarly, it would not be appropriate to extrapolate the digestion 
performance from PSAQ standards to the whole proteome because they also 
reflect - at best - the properties of a subset of proteins in a complex sample.  
 Thus, the proteomics community needs a single-protein standard that (i) 
reflects the digestion properties of a complex protein mixture and (ii), 
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simultaneously allows detailed assessment of multiple sample analysis 
parameters (digestion conditions and rate of proteolysis, LC-MS performance). 
This is especially required in biomarker development studies that involve the 
digestion of highly complex matrices (serum/plasma) and quantify selected 
proteins across multiple samples. To meet this need, we have generated and 
validated a new generic standard, DIGESTIF, that has been specifically designed 
to release indicator peptides directly reflecting how well a generic protein sample 
is digested. In this article, we describe how DIGESTIF can be used to select 
optimal digestion conditions and assess proteolysis efficiency in bottom-up 
proteomics experiments to improve the reliability of MS-based biomarker studies. 
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EXPERIMENTAL SECTION 
 
DIGESTIF molecular modeling and cloning  
 Using the PyMOL Molecular Graphics System software (www.pymol.org), 
the optimal DIGESTIF protein was designed by molecular modeling of three 
different variants, considering different sequential arrangements of the iRT 
peptides in the PBP2x scaffold 40. For the variant displaying the most favorable 
design in terms of theoretical protein solubility and stability, a synthetic gene 
sequence was determined and optimized for E. coli codon usage. This sequence 
was purchased from GeneArt/Life Technologies (Regensburg, Germany). After 
digestion with NdeI and XhoI restriction enzymes (NEB, Evry, France), the 
synthetic gene was inserted into the PET33b vector (Novagen/Merck Millipore, 
Molsheim, France). This vector adds an N-terminal hexahistidine tag to the target 
protein and provides kanamycin resistance. The plasmid was chemically 
transformed into E. coli DH5α cells (NEB) for amplification. After purification, the 
plasmid DNA sequence was verified (LGC Genomics, Berlin, Germany). The 
pET33b-DIGESTIF vector was then transformed into a BL21(DE3) E. coli strain 
(Novagen/Merck Millipore), which is auxotrophic for lysine and arginine 
(genotype: lysA-, argA-). This strain 41 was specifically developed for the 
expression of proteins labeled with different isotopic forms of lysine and arginine. 
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DIGESTIF expression and isotope-labeling 
 Transformed auxotrophic E.coli cells were selected on plates containing 
kanamycin-supplemented LB medium. A positive clone was selected and grown 
in 1 L of a specific medium optimized for isotope labeling. This medium 
contained: M9 minimum salts supplemented with 2 mM MgSO4 and 100 µM 
CaCl2, 0.4% glucose, 50 µg/ml kanamycin, and 100 mg/L each [13C6, 15N4] 
arginine and [13C6, 15N2] lysine (Eurisotop, Saint Aubin, France). When the OD 
reached 0.5, expression of the DIGESTIF protein was induced by adding 1 mM 
IPTG to the media. Cell culture was maintained for 4 h at 37 °C.  
 
DIGESTIF solubilization, purification and refolding 
 E. coli cells were harvested by centrifuging for 20 min at 5000 g and 4 °C. 
The pellet was suspended in 50 mL of Bugbuster (Novagen/Merck Millipore) 
supplemented with lysosyme at 200 µg/mL (Euromedex, Souffelweyersheim, 
France), 1 tablet of Complete™ EDTA Free (Roche Diagnostics, Meylan, France) 
and benzonase at 25 units/µl (Novagen/Merck Millipore). After 30 min at room 
temperature, the cell extract was centrifuged for 30 min at 15 000 g and 4 °C. 
The DIGESTIF protein was present in inclusion bodies. These were solubilized in 
a buffer containing 8 M urea, 20 mM Tris pH 7.5, 500 mM NaCl and 20 mM 
imidazole. The solubilized His-tagged DIGESTIF protein was purified using IMAC 
on Ni-Sepharose 6 Fast flow resin (GE Healthcare, Velizy, France) in accordance 
with the manufacturer’s recommendations. Protein was eluted from the 
purification resin by applying an imidazole gradient. To refold and solubilize the 
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eluted DIGESTIF protein, the purification mixture was submitted to successive 
dialyses in buffers containing 20 mM Tris, 150 mM NaCl and decreasing urea 
concentrations (8/6/4/2/1/0.5/0.25/0 M urea). The purity of the resulting 
DIGESTIF standard was checked by SDS-PAGE analysis and sensitive Imperial 
Protein Stain staining (Thermo Fisher Scientific, Villebon sur Yvette, France). 
Based on this, purity was estimated to be greater than 90% (Supplementary 
Figure S1). DIGESTIF was then quantified using a microBCA assay (Sigma 
Aldrich). 
 
DIGESTIF proteolysis and peptide oxidation  
 For LC-MS/MS analysis and to determine sequence coverage, the 
DIGESTIF standard was digested overnight at 37 °C in-solution using a 1/100 
(w/w) trypsin-to-protein ratio (sequencing grade Trypsin, Promega, 
Charbonnières, France). To assess digestion kinetics, two different trypsin-to-
DIGESTIF ratios were used: 1/100 (w/w) and 1/1000 (w/w). In these assays, 
digestion was also performed at 37 °C, but incubation time varied from 2 min to 
24h, and digestion was stopped by adding formic acid (0.4% final concentration). 
After digestion, peptides were desalted with ZipTip C18 Pipette Tips (Millipore) 
before drying by vacuum centrifugation. In-solution oxidation was performed by 
adding 20 µL of 7% H2O2 / 0.5% formic acid to the sample. After at least 20 
minutes' incubation at room temperature, peptides were injected onto the LC 
system. 
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Serum proteolysis experiments 
 Human male AB serum was obtained from Sigma Aldrich. Serum aliquots 
(6 µl, ~300 µg of serum proteins) were spiked with 1 µg (12.1 pmoles) of 
DIGESTIF (1/300, w/w) and digested into peptides using different protocols 
presented in Table 1. For these experiments, trypsin (sequencing grade) and 
trypsin/Lys-C mix (proprietary composition) were both purchased from Promega. 
Rapigest™ was obtained from Waters. In some experiments, samples were 
reduced using TCEP (2 mM, 30 min in the dark) and alkylated using 
iodoacetamide (10 mM, 30 min) prior to digestion (Figure 4/Test 10, Figure 
7/Test 10). After proteolysis, each sample was spiked with unlabeled DIGESTIF 
peptides which served as quantification standards (12.1 pmoles of each peptide, 
AQUA QuantPro™ peptides, Thermo Fisher Scientific). Samples were desalted 
on C18 Macro SpinColumns (Harvard apparatus, Les Ulis, France). Samples that 
had not been reduced and alkylated were oxidized after proteolysis, as described 
above. 
 
Experiments in human urine and mouse liver lysate 
 A urine sample (1 mL) was obtained from a healthy donor, member of a 
clinical research cohort established for urinary biomarker investigation. The 
protocol for this clinical research was approved by the local hospital’s institutional 
review board, and the donor provided written informed consent for participation in 
this research. Mouse liver (C57BL/6 strain) was collected and provided by an 
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animal research facility operating in line with French and European guidelines 
and regulations for animal testing. Liver lysate was prepared by homogenizing 
frozen tissue at 4 °C in 3 volumes of lysis buffer (250 mM sucrose, Tris 50 mM 
pH 7.4). The homogenate was centrifuged for 10 min at 12 000 g and 4 °C and 
the supernatant was collected before protein quantification using a micro BCA 
assay. DIGESTIF standard (1 µg or 12.1 pmoles) was spiked into 8 µl (equivalent 
300 µg total protein) of mouse liver lysate or 1 mL (equivalent 300 µg total 
protein) of urine, and different proteolysis protocols were assessed (see Table 1 
and Figure 5). For urine samples, Filter aided sample preparation (FASP) using 
10 MWCO spin filters (Merck Millipore, Fontenay sous Bois, France) was 
performed as previously described 42,43. Slight variations on the FASP protocol 
(proteolysis with trypsin or double digestion with trypsin/Lys-C mix, absence or 
presence of reduction/alkylation treatment) were applied as detailed in Table 1 
and Figure 5 (Tests 14, 15 and 16). Before LC-SRM analysis, unlabeled 
DIGESTIF peptides serving as quantification standards were added to the 
samples and the digests were desalted on Macrospin C18 columns (Harvard 
apparatus). 
 
Biomarker quantification experiment 
 A plasma sample from a patient suffering from drug-induced liver injury 
was collected in the hepatology department at Grenoble university hospital. This 
patient was a member of a clinical research cohort established to assess new 
liver injury biomarkers. The research protocol was approved by the hospital’s 
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institutional review board, and the patient provided written informed consent for 
participation in the study. The blood sample was taken upon hospital admission 
in a BD P100 tube (BD Biosciences, le Pont de Claix, France). It was centrifuged 
at 2200 g for 10 min to obtain plasma. This was immediately aliquoted and stored 
at -80 °C. Aliquots (3 µl each) of the patient's plasma sample were spiked with 
0.5 µg (6 pmoles) of the DIGESTIF standard and were submitted to different 
proteolysis protocols, as described in Table 1 (Tests 1, 7, 8, 9, 10, 12 and 13). 
Plasma digests were either oxidized or alkylated as indicated for the different 
tests. 
 
LC-SRM analyses 
 All SRM transition lists used to selectively monitor DIGESTIF peptides 
were generated using Skyline 22 (Table 2). LC-SRM runs were used to refine the 
SRM transition lists and to schedule acquisition. A similar procedure was 
followed when developing the SRM method to monitor the DIGESTIF peptides in 
combination with biomarker signature peptides in plasma. The following analyses 
were performed at the different sites:  
 Site 1 
 LC-SRM analyses were performed on a 4000QTrap hybrid triple 
quadrupole/ion trap mass spectrometer (AB Sciex) equipped with a TurboV 
source (AB Sciex) and controlled by Analyst software (version 1.5, AB Sciex). 
The instrument was equipped with an Ultima 3000 LC system (Thermo 
Scientific). Chromatography was performed using a two-solvent system 
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combining solvent A (2% acetonitrile, 0.1% formic acid) and solvent B (80% 
acetonitrile, 0.1% formic acid). 100 µg of protein digest (10 µl pick-up injection) 
was separated on a Kinetex XB-C18 column, 2.1 x 10 cm, 1.7 µm, 100 Å 
(Phenomenex, Le Pecq, France). Peptide separation was achieved using a linear 
gradient from 4% to 45% B over 25 min, and from 45% to 90% B in 5 min at a 
flow rate of 50 µl/min. MS data were acquired in positive mode with an ion spray 
voltage of 5500 V; curtain gas was used at 15 p.s.i. and the interface heater 
temperature was set to 375 °C. Collision exit, declustering and entrance 
potentials were set to 19, 12 and 55 V, respectively. The appropriate collision 
energy was calculated based on the following equations: CE (Volts) = 0.44*m/z + 
4 for doubly-charged precursors and CE (Volts) = 0.5*m/z + 5 for triply-charged 
precursors. Analyses combined in the same run: (1) a precursor ion scan 
between 400-1400 m/z as a survey scan for Information Dependent Acquisition 
(IDA), (2) an Enhanced Product Ion (EPI) scan with a scan speed of 4000 
amu/sec and a dynamic fill time for optimal MS/MS analysis, (3) an SRM 
acquisition with Q1 and Q3 quadrupoles operating at unit resolution. For 
scheduled SRM analyses, the acquisition time windows and target scan time 
were set to 90 sec and 1 sec, respectively. This corresponds, for 
chromatographic peaks with a base width of 30 sec, to acquisition of 30 points 
per LC peak.  
 Sites 2 and 3 
 At sites 2 and 3, SRM was performed on a TSQ Quantum Ultra EMR triple 
quadrupole mass spectrometer (Thermo Scientific) operated with Xcalibur 2.0.7 
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(Thermo Scientific). For each analysis, 1 µg of protein digest (1 µl pick-up 
injection) was injected via the associated nano-LC system (Eksigent). Samples 
were automatically injected into a 10-µl sample loop and loaded onto an 
analytical column. The analytical column (8 cm length × 75 µm internal diameter) 
was packed in-house with Magic C18 AQ beads (5 µm, 100 Å; Michrom 
Bioresources). Peptide mixtures were delivered to the analytical column at a flow 
rate of 500 nl/min of buffer A (5% acetonitrile, 0.2% formic acid) for 18 min and 
then eluted using a gradient of acetonitrile (10%–35%; 0.36%/min) in 0.2% formic 
acid at a flow rate of 250 nl/min. Collision energies (CE) were calculated 
according to the following formulas: CE = 0.034×m/z+3.314 (2+) and CE = 
0.044×m/z+3.314 (3+). MS data were acquired in positive mode with an ion spray 
voltage of 1600 V and a capillary temperature of 270 °C. Scan speed was set to 
20 ms per scan event, which resulted in a cycle time of 1.5 sec. For 
measurements, the Q1 resolution was set to 0.4 and the Q3 resolution to 0.7 at 
full width half maximum.  
 
Data analysis 
 LC-SRM data were analyzed using Skyline 22. Signals with a signal to 
noise ratio < 3 (i.e. peak height to background median < 3) or with obvious matrix 
interferences (experiments in biological matrices) were systematically excluded 
from the analysis. For absolute quantification of DIGESTIF peptides, coelution 
profiles of the labeled and unlabeled versions of each peptide were verified. 
Signals with a signal to noise ratio > 10 were considered for quantification.  
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Labeled/unlabeled peak area ratios were calculated for each SRM transition. 
Ratios obtained from the different SRM transitions were used to calculate the 
corresponding average peptide ratio. Peptide quantities in the processed sample 
were deduced from the ratios obtained for the different peptides and the 
quantities of spiked peptide standards.  
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RESULTS 
 
Design of DIGESTIF standard 
 The major goal of the DIGESTIF project was to generate and test a 
universally applicable reference protein to assess the efficiency of trypsin 
digestion and LC-MS performance in bottom-up proteomics protocols. To 
achieve these goals, the DIGESTIF standard was designed as an isotope-
labeled full-length protein which could be spiked into biological samples and 
digested with trypsin alongside endogenous proteins. The DIGESTIF standard 
included in its sequence the 11 peptides of the iRT peptide set previously 
described by Escher and colleagues. These peptides span a wide range of 
hydrophobicity and eluted at regular intervals using C18 reverse-phase columns 
and standard LC gradients 20. 
 To simulate the differing digestion properties encountered in a complex 
protein mixture, iRT peptide cleavage sites were flanked with amino acids to 
either favor or hamper trypsin digestion (Figure 1). These amino acids were 
chosen based on an in-depth study of trypsin cleavage rules 34. Depending on di-
amino acid motifs present at cleavage sites, the iRT peptides contained in the 
DIGESTIF standard were classified in 3 categories: those that would be easily 
released, those that would be released at a moderate rate and those that would 
be difficult to release (Supplementary Figure S2). The sequences corresponding 
to these flanked iRT peptides were inserted into the coding sequence of the 
soluble PBP2x protein scaffold from Streptococcus pneumoniae 44 (Figure 1), 
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and molecular modeling was used to determine the most suitable sequential 
arrangement of the iRT peptides in the PBP2x permissive regions (with respect 
to solubility and stability) based on three prototype designs (see experimental 
section). As proteolysis rate is also influenced by secondary and tertiary 
structure, a peptide from the β7 sheet of the PBP2x core (peptide 
NLVQPIVVGTGTK) was also included in the panel of indicator peptides. 
 The DIGESTIF construct was expressed in E. coli as a ([13C6, 15N4] 
arginine and [13C6, 15N2] lysine) isotopically labeled protein. Isotope incorporation 
was measured and found to be greater than 99% (Supplementary Figure S1). 
The purified, refolded and labeled protein standard will hereafter be referred to as 
DIGESTIF and is the form used in all the experiments described in this paper. 
The isotope labeling of DIGESTIF makes it possible to distinguish between iRT 
peptides released by proteolytic digestion of DIGESTIF and the commercially 
available, unlabeled iRT peptides 20. 
 
Features and kinetics of DIGESTIF proteolysis 
 Before using the DIGESTIF standard in complex protein matrices, we 
characterized its behavior as sole sample constituent by measuring the peptides 
generated upon trypsin digestion. Pure DIGESTIF standard was subjected to 
digestion with trypsin at 1/100 (w/w) enzyme-to-protein ratio for 24 h at 37 °C. An 
oxidation step (transforming cysteine into cysteic acid) was included prior to LC-
MS analysis for optimal detection of the missed-cleaved, cysteine-containing 
peptide TACKDGLDAASYYAPVR 45. We chose to use cysteine oxidation rather 
than regular reduction/alkylation. As oxidation is performed after digestion, it 
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cannot have an impact on proteolysis. After peptide oxidation, the digest was 
analyzed by LC-MS/MS on an Orbitrap mass spectrometer (Thermo Scientific). 
The peptides identified covered 82% of the DIGESTIF sequence (Figure 2A), 
including all iRT peptides. Among the observed iRT peptides, the 
ADVTPADFSEWSK peptide (iRT peptide h) was detected with an oxidized 
tryptophan residue. This is probably due to the oxidation step. As tryptophan 
oxidation can yield several oxidation products, this peptide was not monitored in 
subsequent experiments. A few iRT peptides were detected, at low intensities, in 
missed-cleaved forms. These consisted of the following: CARYILAGVENSK (iRT 
peptide d), YILAGVENSKTAAR (iRT peptide d) (data not shown), and the 
expected - and by far the most prevalent - TACKDGLDAASYYAPVR (iRT 
peptide g) (Figure 2B). 
 Next, to determine the kinetics of iRT peptide release during DIGESTIF 
proteolysis, pure DIGESTIF standard was submitted to tryptic digestion under 
differing conditions. Two different enzyme-to-protein ratios were tested: (i) 1/100 
(w/w) (standard concentration), and (ii) 1/1000 (w/w) which is 10-times below 
supplier’s recommendations. We used this low concentration to simulate sub-
optimal sample processing conditions. In addition to the variation in enzyme 
concentrations, the digestion reaction was stopped at different time points to 
determine the kinetics of peptide release. Analysis of the peptides released was 
performed using LC-SRM to enhance detection sensitivity (Figure 3). This is 
crucial, as at early stages of the digestion reaction peptides will only be present 
in minute amounts. In these assays, all iRT peptides were quantified using a 
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label-free strategy based on the signal provided by the best transition 
(Supplementary Table ST1). Characterization of DIGESTIF proteolysis was 
further refined and improved by quantifying four selected peptides based on 
signal comparison with unlabeled peptide standards. The four selected peptides 
were: iRT peptide i (GTFIIDPGGVIR, predicted to be easily cleaved), iRT peptide 
g (DGLDAASYYAPVR, predicted to be difficult to digest), missed-cleaved iRT 
peptide g (TACKDGLDAASYYAPVR) and the peptide from the PBP2x protein 
core (peptide NLVQPIVVGTGTK) (Figure 3B).  
 With a trypsin-to-protein ratio of 1/100, all iRT peptides flanked with 
“digestion-promoting” cleavage sites (Figure 1) were rapidly released. Steady 
state levels of these peptides were attained after 5 hours of incubation. iRT 
peptides predicted to be difficult to cleave, i.e. iRT peptides c 
(VEATFGVDESNAK) and g (DGLDAASYYAPVR) did not reach a plateau level, 
even after 24 h of proteolysis (Figure 3B and Supplementary Table ST1). The 
signal intensity for the missed-cleaved version of peptide g, 
TACKDGLDAASYYAPVR, peaked at 5 h of digestion and decreased thereafter 
(when the correctly cleaved peptide g started to become detectable); while the 
PBP2x core peptide (NLVQPIVVGTGTK) displayed regular, slow digestion 
kinetics in these conditions, probably due to its protected position in the PBP2x 
protein core 44. In the alternative enzymatic conditions, when using a trypsin-to-
protein ratio of 1/1000, even with prolonged digestion times digestion did not 
reach completion for most of the peptides monitored (Figure 3, Supplementary 
Table ST1). Based on these results, we conclude that the release of iRT peptides 
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(which show distinct digestion kinetics), directly reflects protein susceptibility to 
trypsin proteolysis, as a function of primary sequence. The release of the PBP2x 
core peptide evidences the influence of protein structure on trypsin activity. In 
summary, the DIGESTIF standard can be used as a model reflecting the 
digestion properties of a broad range of proteins.   
 
Characterizing DIGESTIF proteolysis in human serum 
 Our initial aim in designing the DIGESTIF standard was to improve the 
reliability of MS-based analyses, in particular for biomarker evaluation studies. It 
was thus necessary to assess how DIGESTIF performed in the complex biofluids 
commonly used in this type of study, such as serum or plasma. For this purpose, 
serum aliquots (6 µL each) from a healthy donor were spiked with 1 µg of 
DIGESTIF standard. Considering molar abundance, DIGESTIF standard ranked 
below the 30 to 50 most abundant plasma proteins. Samples were submitted to 
proteolysis using eight reaction conditions (Figure 4). These included both 
classical procedures and sub-optimal proteolysis conditions that would reflect 
possible mistakes made when executing the protocol. The resulting peptide 
samples were analyzed by LC-SRM. All the peptides released were quantified 
using a label-free strategy (Supplementary Table ST2). Three DIGESTIF 
peptides (iRT peptides g and i, and PBP2x core peptide) were also quantified 
using unlabeled peptide standards to precisely evaluate the efficiency of 
proteolysis across the different conditions (Figure 4). These experiments showed 
that the release of iRT peptides from DIGESTIF was reduced by a low trypsin-to-
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protein ratio, sub-optimal incubation temperature (30 °C or 23 °C) or acidic pH. In 
line with results reported in previous studies 24,28, we found that the best 
proteolysis protocol was based on the use of a trypsin/Lys-C enzymatic mixture 
and urea for protein denaturation (Figure 4, Test 9). In these conditions, all iRT 
peptides and the PBP2x core peptide were more readily detected than when 
samples were digested with trypsin alone (Test 1) (Figure 4 and Supplementary 
Table ST2). In quantitative terms, this improvement corresponds to an increase 
in peptide abundances by between 1.2-fold (PBP2x core peptide) and 22.4-fold 
(iRT peptide g) compared to Test 1 (Figure 4). Interestingly, treating the serum 
sample with TCEP and iodoacetamide before trypsin digestion (Test 10) also 
promoted the release, and thus detection, of iRT peptides from DIGESTIF 
(Figure 4 and Supplementary Table ST2), although the improvement was not as 
marked as in the trypsin/Lys-C mix plus urea conditions (Test 9). From these 
results, we conclude that DIGESTIF can be used to evaluate digestion efficiency 
in the complex matrices typically used in biomarker evaluation studies, and that it 
is useful in identifying conditions where proteolysis is incomplete. It also allows to 
select the optimal digestion protocol. 
 
Characterizing DIGESTIF proteolysis in human urine and mouse liver lysate 
 As the peptides generated from DIGESTIF are artificial, this standard can 
potentially be used in combination with any biological sample. To demonstrate 
this applicability, we went on to characterize its performance in two additional 
biological matrices: human urine and mouse liver lysate. In these tests, both 
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samples were spiked with DIGESTIF standard before being submitted to different 
proteolysis protocols (Figure 5). The iRT peptides g and i, and PBP2x core 
peptide were quantified using LC-SRM and unlabeled peptide standards. In 
human urine, these iRT peptides were more efficiently released when trypsin was 
used in combination with reduction/alkylation (Test 10, Figure 5, Supplementary 
Table ST2). As it was impossible to apply the proteolysis protocol recommended 
by the trypsin/Lys-C mix manufacturer (Test 9) with urine samples as it would 
have led to excessive sample dilution, we used the trypsin/Lys-C mix in 
combination with FASP (Table 1). This latter protocol was also found efficient to 
release the three targeted iRT peptides (Figure 5). In summary, our results 
confirm that a protocol combining reduction/alkylation and trypsin digestion is 
appropriate for sensitive detection of urinary proteins 46.  
 Mouse liver lysate is a more complex and more concentrated matrix than 
urine. In this sample, only 8 out of the 10 monitored iRT peptides could be 
detected (data not shown). The released amounts of indicator peptides (iRT 
peptides g, i and the PBP2x core peptide) indicate that the proteolysis using 
trypsin/Lys-C mix clearly outperformed the other protocols tested (Test 9, Figure 
5, Supplementary Table ST2).  
 In conclusion, these experiments confirm the importance of adapting and 
assessing proteolysis protocols for each type of biological matrix 15,16,24,28,30. The 
DIGESTIF standard undoubtedly facilitates protocol comparison during these 
tests. 
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Improving MS-based biomarker studies using DIGESTIF 
 To test the suitability of DIGESTIF in the context of clinical biomarker 
detection, three biomarkers were investigated in a plasma sample from a patient 
with drug-induced liver injury. The biomarkers investigated were the following: 
alanine aminotransferase 1 (ALAT1) - which is routinely investigated in clinical 
settings -, liver fatty acid binding protein (L-FABP), and alcohol dehydrogenase 1 
(ADH1) - which have both been described as potential liver injury biomarkers 
47,48
. The patient's plasma sample was spiked with the DIGESTIF standard 
before sample digestion to assess proteolysis efficiency. As in previous 
experiments, seven commonly used digestion protocols were compared (Table 1, 
Tests 1, 7, 8, 9, 10, 12 and 13), and the resulting samples were analyzed using 
LC-SRM (Figure 6). Label-free data analysis revealed two main classes of 
DIGESTIF peptides: (i) peptides that were readily detected across all proteolysis 
conditions (iRT peptides b, c, d, i and the PBP2x core peptide); and (ii) peptides 
that were preferentially observed in the conditions applied in Test 9 and Test 13 
(iRT peptides a, e, f, g, k and l) (Figure 7, Supplementary Table ST3). Besides 
monitoring iRT peptide release, we also determined which protocol was most 
efficient for the simultaneous and sensitive detection of the 3 targeted 
biomarkers. This turned out to be Test 9 (trypsin/Lys C with urea; Figure 6 lower 
panel), confirming our assumption that some biomarkers (here ADH1, ALAT1) 
are very sensitive to variations in proteolysis conditions (Figure 7) 17,38,49. 
Together, these results demonstrate that the DIGESTIF standard, particularly iRT 
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peptides a, e, f, g, k and l, can be used to identify optimal proteolysis protocols 
for sensitive biomarker detection. 
 
Multi-site assessment of DIGESTIF in a serum matrix 
 MS-based biomarker assays are destined to be used in many laboratories 
and at different times, conditions which are very difficult to standardize. 
Therefore, we next examined how the DIGESTIF standard could be used to 
assess digestion efficiency and reproducibility across different laboratories. For 
these experiments, DIGESTIF (1 µg) was spiked into a serum sample (6 µl) 
before proteolysis in three different laboratories. The same protocols (Tests 1, 7, 
8, 11 and 12, Table 1) and the same reagents (but different batches) were used 
in all three laboratories, and samples were analyzed by LC-SRM. Quantification 
data obtained for the peptides released were then cross-compared (Figure 8, 
Supplementary Table ST4). Once again, proteolysis efficiency was seen to vary 
extensively between protocols, but interestingly it also varied quite a lot between 
laboratories, particularly in sub-optimal conditions. However, as previously 
noticed, the “double-digestion” protocol, using a trypsin/Lys-C mix in the 
presence of urea (Test 11), was clearly identified as the best for human serum 
(Figure 8, Supplementary Table ST4). In these conditions, compared to standard 
trypsin proteolysis (Test 1), across the 3 laboratories, iRT peptides i 
(GTFIIDPGGVIR) and g (DGLDAASYYAPVR) were released 5.2 (± 5.7) and 6.0 
(± 1.4) times more effectively, respectively. In conclusion, DIGESTIF clearly 
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identified the most efficient protocol when comparing inter-laboratory results. It 
also unequivocally highlighted inter-laboratory variations in digestion efficiency.  
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DISCUSSION 
 
 In this article we present DIGESTIF, a generic standard for use in bottom-
up proteomics analyses. This standard can be used to verify the quality of all the 
steps in the sample treatment workflow from digestion to LC-MS analysis as part 
of intra- and inter-laboratory quality control. 
 The DIGESTIF standard consists in a PBP2x protein scaffold 40, to which 
the sequences corresponding to the set of iRT peptides 20 have been added. This 
scaffold was chosen because previous experiments had demonstrated that 
several of its regions were structurally permissive for engineering. Thus, removal, 
substitution or insertion of amino acids in these regions has little impact on the 
core structure, solubility and functionality of the engineered PBP2x protein 
variants 40. The PBP2x scaffold thus serves several purposes in the context of 
the DIGESTIF standard: (1) it carries and exposes iRT peptides 20 to trypsin 
digestion; (2) it favors solubility and stability of the whole standard; (3) it 
facilitates the use of the standard by providing a single reagent.   
 Bottom-up proteomics workflows involve three main steps: proteolysis, 
liquid chromatography, and mass spectrometry analysis. Proteolysis is an 
essential step. However, conversion of proteins into peptides remains difficult to 
standardize and is often not reproducible. Although Piehowski and coworkers 50 
estimate that protein digestion only accounts for 3.1% of intra-laboratory 
technical variability, several inter-laboratory studies (including this work) have 
indicated a higher variability of trypsin digestion when the same sample is treated 
at different sites 17,51. This is important to take into consideration as variations in 
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proteolysis will have a direct impact on peptide recovery, and thus detection 
sensitivity. Quantitative experiments using labeled proteins as quantification 
references (SILAC, PSAQ) 38,52 will not be dramatically affected by these 
variations, but in label-free or AQUA experiments 24, digestion yields will directly 
affect quantification accuracy, and thus hamper attempts to discover or use 
protein biomarkers. Percy and colleagues 23 were the first to present a dedicated 
tool to standardize and attempt to benchmark the entire proteomics-based 
biomarker detection workflow, including proteolysis. However, this tool was only 
adapted for use in human plasma samples. The DIGESTIF standard presented 
here overcomes this limitation as it can assess the general efficiency of 
proteolysis, whatever the composition and properties of the sample. DIGESTIF 
combines several quality control aspects in a single reagent whose main purpose 
is to check the quality and efficiency of digestion. This was made possible 
through careful design. Indeed, unlike most other standards (e.g. QconCATs), 
DIGESTIF is not optimized for efficient digestion. Rather, it releases indicator 
peptides progressively, directly reflecting the overall digestion performance in 
complex and heterogenous protein samples. Hence, DIGESTIF mimics the 
properties of a broad range of proteins and, as presented here, can be used to 
establish and optimize the digestion protocol for any sample, regardless of the 
properties of the matrix or specific target proteins, or the type of MS-based 
detection employed. Once an optimized digestion protocol has been established, 
DIGESTIF can be used to monitor digestion efficiency over multiple experiments.  
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 To simultaneously enable quality control of the LC step with our standard, 
we chose to integrate iRT peptides into its sequence. These peptides were 
specifically designed to distribute evenly over a standard reverse-phase LC 
gradient 20. Alternatives to the iRT peptide set could have been used. Indeed, we 
also tested the QCAL peptides presented by Eyers and coworkers 19 as part of 
our initial selection. However, as five of the QCAL peptides co-eluted in our 
gradient conditions (data not shown), these peptides were not deemed suitable 
for our purposes. Another advantage of the iRT peptide set is that, with SRM 
measurements, automated target validation is possible using mProphet or 
Skyline 21,22.   
 In addition to monitoring digestion efficiency and reproducibility, the 
DIGESTIF standard will be particularly useful in the context of biomarker studies, 
where false negative results can be problematic. By indicating the degree of 
digestion, DIGESTIF can be used to rate the quality of sample processing based 
on reliable and objective criteria (e.g. release of iRT peptide l, see Figure 7). This 
will help to exclude poorly-digested samples from evaluation. Likewise, 
DIGESTIF will make data comparison between different studies more reliable, 
while also helping to eliminate false positives that might simply be due to 
differences between digestion protocols. This is also essential for comparative 
(especially label-free) proteomics approaches where conclusions will be drawn 
based on abundance differences between two or more experimental states. 
 The DIGESTIF standard presented in this publication will be made 
available to researchers and is expected to be commercially available as a 
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validated product for the broad proteomics community. More extensive 
experience with the DIGESTIF standard will help to refine and validate its use in 
a range of different contexts. We believe that this standard will help researchers 
to select robust proteolysis protocols, and to define quality control criteria for 
biomarker experiments based on defined relationships (e.g. ratios) of a subset of 
DIGESTIF peptides. This will be further supported by improved versions of the 
standard which will include new features to check for protein modifications 
(glycosylations), for chemical reactions occurring during sample processing, or 
use other proteases than trypsin. 
 
 In conclusion, DIGESTIF can be used to: (i) benchmark digestion reagents 
(i.e. proteases) before establishing digestion protocols 25,31, (ii) select the best 
conditions for sample proteolysis 26,28,29, (iii) check the efficiency of digestion, (iv) 
identify poorly digested samples and correct for variations in digestion efficiency, 
if necessary. We believe that DIGESTIF has great potential to enhance the 
quality and reproducibility of bottom-up proteomics experiments. 
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FIGURE LEGENDS 
 
Figure 1. Design of the DIGESTIF standard 
(A) The DIGESTIF protein was assembled using iRT peptides and a protein 
scaffold called PBP2x mini 40 from which N-terminal sequences (grey) have been 
removed. iRT peptide cleavage sites were flanked by amino acids that are known 
to influence digestion efficiency, as determined by Rodriguez and coworkers  
(supplementary Figure S2). Based on di-amino acid motifs surrounding cleavage 
sites, iRT peptides were designed to fall into one of 3 categories: sequences in 
green correspond to easily released peptides, orange lettering indicates 
moderately released peptides, and red peptides are classed as difficult to cleave. 
(B) In the final DIGESTIF protein the iRT peptides are distributed over three 
predetermined insertion sites in the PBP2x mini sequence. The optimal 
placement of the iRT peptides was determined by molecular modeling (see 
Experimental section for details). A hexahistidine tag (blue) inserted at the 
extreme N-terminus was used to purify the recombinant protein. (C) Full amino 
acid sequence of the DIGESTIF protein. PBP2x mini sequences are indicated in 
grey, iRT peptides in green, orange or red. 
 
Figure 2. LC-MS/MS and LC-SRM analysis of DIGESTIF standard. 
Pure DIGESTIF was submitted to in-solution trypsin digestion followed by 
oxidation. The digest was analyzed using LC-MS/MS on an Orbitrap mass 
spectrometer equipped with a nanoLC chromatography system. MS/MS data 
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were processed automatically using Mascot Daemon software (version 2.3, 
Matrix Science). Peptides were identified using a custom-built database 
containing the DIGESTIF sequence (A). The peptides identified from the 
DIGESTIF sequence are shown in blue. Boxes indicate the iRT peptides and the 
PBP2x core peptide. (B) The digest was also used to develop a scheduled LC-
SRM method targeting iRT peptides, the missed-cleaved iRT peptide g and the 
PBP2x core peptide. The extracted ion chromatogram for the corresponding 
SRM transitions is presented. 
 
Figure 3. Time-course analysis of DIGESTIF proteolysis. 
Samples containing 2 µg of pure DIGESTIF standard were submitted to trypsin 
digestion either with a 1/100 (w/w) or a 1/1000 (w/w) enzyme-to-protein ratio for 
different periods of time. Completion of digestion was monitored by SDS-PAGE 
analysis (1 µg of hydrolyzed DIGESTIF loaded) and silver staining (A) or 
quantitative LC-SRM analysis (B). Absolute quantities of 4 DIGESTIF peptides 
(iRT peptides i and g, missed-cleaved iRT peptide g and PBP2x core peptide) 
were estimated using LC-SRM and unlabeled peptide standards. The quantities 
were plotted as a function of the duration of digestion. Each data point 
corresponds to the mean ± standard deviation (n = 3 SRM transitions per 
peptide, see also Supplementary Table ST1). 
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Figure 4. DIGESTIF proteolysis in serum. 
Serum samples (6 µl aliquots) were spiked with DIGESTIF standard (1 µg) and 
submitted to 8 different digestion protocols. These included 3 classical 
procedures (Tests 1, 9 and 10) and 5 sub-optimal proteolysis conditions that 
would reflect mistakes made when executing the protocol (Tests 2 to 6). The 
efficiency of proteolysis was assessed by LC-SRM to determine the quantities of 
3 DIGESTIF peptides (iRT peptides i and g, and PBP2x core peptide) after 
adding unlabeled peptides (AQUA) as quantification standards. Each bar 
corresponds to the mean ± standard deviation, calculated from 3 technical 
replicates (see also Supplementary Table ST2). 
 
Figure 5. DIGESTIF proteolysis in human urine and mouse liver lysate. 
The human urine and mouse liver lysate samples were spiked with DIGESTIF 
standard prior to digestion using different protocols (Tests 1, 9, 10, 14, 15 or 16). 
Samples were then analyzed by LC-SRM targeting iRT peptides i and g, and the 
PBP2x core peptide. The amount of released peptide was measured using 
unlabeled peptide standard and is reported in the different digestion conditions. 
To increase detection sensitivity, with urine samples, LC-SRM analysis was 
performed using a QTrap6500 mass spectrometer. Due to the reduced m/z range 
(400-1000) provided by this machine, some transitions had to be changed 
(supplementary Table ST2). 
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Figure 6. LC-SRM chromatograms of DIGESTIF standard peptides and liver 
injury biomarker peptides in a patient plasma sample.  
A plasma sample from a patient suffering from drug-induced liver injury was 
spiked with DIGESTIF standard. Aliquots of the plasma sample were digested by 
applying seven different proteolysis protocols (Tests 1, 7, 8, 9, 10, 12 and 13, 
see Table 1) and analyzed by LC-SRM. Targeted peptides included those 
released from DIGESTIF, and 4 signature peptides from 3 liver biomarkers (L-
FABP, ALAT1, ADH1) (see Table 2). The upper chromatogram was obtained 
when trypsin was used alone for proteolysis (Test 1). The chromatogram for 
samples digested with trypsin/Lys-C mix in the presence of urea (Test 9) is 
presented in the lower panel. The y-axis scale is identical in both chromatograms 
to facilitate identification of differences in signal intensity. The peptides best 
suited for identification of differences in digestion efficiency are indicated by 
dotted lines between the two spectra. 
 
Figure 7. Detection of liver biomarkers in plasma using DIGESTIF standard 
and LC-SRM. 
A plasma sample from a patient with drug-induced liver injury was spiked with 
DIGESTIF standard. The plasma sample was digested using seven different 
proteolysis protocols (Tests 1, 7, 8, 9, 10, 12 and 13, see Table 1) and analyzed 
by LC-SRM, as described in the methods section. Label-free LC-SRM data were 
processed and SRM signal intensity (sum of peak area values obtained for 3 
SRM transitions) was determined for each peptide in each digestion condition. 
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Figure 8. Multi-site evaluation of serum digestion protocols using DIGESTIF 
standard. 
Serum sample preparation, spiking with DIGESTIF, sample digestion and LC-
SRM analysis was performed in 3 different laboratories, as described in the 
experimental section. At each site, and for the 5 different proteolysis protocols 
(Table 1), 4 peptides (iRT peptides i and g, missed-cleaved iRT peptide g and 
PBP2x core peptide) were quantified by LC-SRM by comparison to unlabeled 
(AQUA) peptide standards. Each bar corresponds to the mean ± standard 
deviation calculated based on 3 SRM transitions.  
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Table 1. Protocols used for proteolysis 
Test 
number Enzyme 
Enzyme/protein 
ratio (w/w) Additive 
Incubation 
Remarks 
Temperature Time 
Test 1 Trypsin 1/20 No 37°C 5 h  
Test 2 Trypsin 1/100 No 37°C 5 h  
Test 3 Trypsin 1/1000 No 37°C 5 h  
Test 4 Trypsin 1/20 No 30°C 5 h  
Test 5 Trypsin 1/20 No 23°C 5 h  
Test 6 Trypsin 1/20 No 37°C 5 h Digestion was performed in sodium citrate (pH 2.2) 
Test 7 Trypsin 1/20 No 37°C 24 h  
Test 8 Trypsin/Lys-C 1/20 No 37°C 5 h  
Test 9 Trypsin/Lys-C 1/20 Urea 37°C 5 h 
Sample was incubated for 1 h 30 in 4 M urea. The urea 
concentration was reduced to 1 M by dilution, and 
digestion was allowed to proceed for 3 h 30. 
Test 10 Trypsin 1/20 TCEP and iodoacetamide 37°C 5 h 
Sample was reduced (TCEP 2 mM, 30 min) and 
alkylated (iodoacetamide 10 mM, 30 min in the dark) 
before trypsin digestion 
Test 11 Trypsin/Lys-C 1/20 Urea 37°C 24 h 
Sample was incubated for 3 h in 4 M urea. The urea 
concentration was reduced to 1 M by dilution, and 
digestion was allowed to proceed for 21 h 
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Table 1 (continued). 
Test 
number Enzyme 
Enzyme/protein 
ratio (w/w) Additive 
Incubation 
Remarks 
Temperature Time 
 
Test 12 Trypsin 1/20 Rapigest 0.1% 37°C 5 h  
Test 13 Trypsin 1/20 Rapigest 0.1% 37°C 5 h Sample was heated to 100 °C for 5 min before adding 
trypsin 
Test 14 Trypsin 1/20 TCEP and iodoacetamide 37°C 5 h 
FASP protocol was applied with reduction (TCEP 2 
mM, 30 min) and alkylation (iodoacetamide 10 mM, 30 
min in the dark). Trypsin digestion was allowed to 
proceed for 5 h. 
Test 15 Trypsin/Lys-C 1/20 Urea 37°C 5 h 
FASP protocol was applied  without reduction and 
alkylation treatment. Digestion was performed 1 h 30 in 
4 M urea. Then, urea concentration was reduced to 1 
M and hydrolysis was allowed to proceed for 3 h 30. 
Test 16 Trypsin/Lys-C 1/20 
TCEP, 
iodoacetamide 
and urea 
 
37°C 5 h 
FASP protocol was applied with reduction (TCEP 2 
mM, 30 min) and alkylation (iodoacetamide 10 mM, 30 
min in the dark). Digestion was performed 1 h 30 in 4 
M urea. Then, urea concentration was reduced to 1 M 
and hydrolysis was allowed to proceed for 3 h 30. 
All digestion reactions were performed in 40 mM ammonium bicarbonate buffer (except for Test 6)  
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Table 2. Peptides investigated and their SRM transitions 
 
 
Peptide sequence Peptide features SRM transitions 
Precursor 
Q1 m/z 
Fragment 
Q3 m/z 
LGGNEQVTR iRT peptide a 492.3 870.4 (y8) 
  492.3 813.4 (y7) 
  492.3 642.3 (y5) 
GAGSSEPVTGLDAK iRT peptide b 648.8 937.5 (y9) 
  648.8 808.5 (y8) 
 
 648.8 612.3 (y6) 
VEATFGVDESNAK iRT peptide c 687.8 1146.5 (y11) 
 
 687.8 974.5 (y9) 
 
 687.8 827.4 (y8) 
YILAGVENSK iRT peptide d 551.3 825.5 (y8) 
  551.3 712.4 (y7) 
 
 551.3 641.3 (y6) 
TPVISGGPYEYR iRT peptide e 674.8 1051.5 (y9) 
  674.8 938.4 (y8) 
  674.8 851.4 (y7) 
TPVITGAPYEYR iRT peptide f 688.9 966.5 (y8) 
  688.9 865.4 (y7) 
 
 688.9 737.3 (y5) 
DGLDAASYYAPVR iRT peptide g 704.3 865.4 (y7) 
 
 704.3 615.3 (y5) 
 
 704.3 452.3 (y4) 
DGLDAASYYAPVR iRT peptide g 699.3 855.4 (y7) 
 
 699.3 605.3 (y5) 
 
 699.3 442.3 (y4) 
TACox3KDGLDAASYYAPVR Missed-cleaved  
iRT peptide g 
623.0 778.4 (y6) 
 
 623.0 615.4 (y5) 
 
 623.0 452.3 (y4) 
TACox3KDGLDAASYYAPVR Missed-cleaved  
iRT peptide g 
617.0 768.4 (y6) 
  617.0 605.4 (y5) 
 
 617.0 442.3 (y4) 
GTFIIDPGGVIR iRT peptide i 627.9 836.5 (y8) 
 
 627.9 723.4 (y7) 
 
 627.9 608.4 (y6) 
GTFIIDPGGVIR iRT peptide i 622.9 826.5 (y8) 
 
 622.9 713.4 (y7) 
 
 622.9 598.4 (y6) 
GTFIIDPAAVIR iRT peptide k 641.9 864.5 (y8) 
 
 641.9 751.4 (y7) 
 
 641.9 636.4 (y6) 
Labeled peptides from the DIGESTIF are mentioned with the C-terminal, isotope-labeled amino 
acid, in bold. Italicized peptides were used for absolute quantification (light unlabeled peptide 
standards). Cysteine trioxidation (ox3) modification state is indicated. 
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Table 2 (continued). 
 
Peptide sequence Peptide features SRM transitions 
Precursor 
Q1 m/z 
Fragment 
Q3 m/z 
LFLQFGAQGSPFLK iRT peptide l 780.9 1059.6 (y10) 
  780.9 912.5 (y9) 
  780.9 656.4 (y6) 
NLVQPIVVGTGTK PBP2x core peptide 667.4 1106.7 (y11) 
  667.4 1007.6 (y10) 
 
 667.4 879.5 (y9) 
NLVQPIVVGTGTK PBP2x core peptide 663.4 1098.7 (y11) 
 
 663.4 999.8 (y10) 
 
 663.4 871.5 (y9) 
AIGLPEELIQK L-FABP signature 
peptide 
605.9 856.5 (y7) 
  605.9 630.4 (y5) 
 
 605.9 428.7 (y7) 
TVVQLEGDNK L-FABP signature 
peptide 
551.8 902.5 (y8) 
  551.8 675.3 (y6) 
  551.8 562.2 (y5) 
LLVAGEGHTR ALAT1 signature 
peptide 
526.8 727.3 (y7) 
  526.8 656.3 (y6) 
  526.8 413.7 (y8) 
FSLDALITHVLPFEK ADH1 signature peptide 577.3 791.9 (y14) 
  577.3 748.4 (y13) 
  577.3 691.9 (y12) 
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Supplementary Table ST1. Label-free analysis of peptide release during 
DIGESTIF proteolysis. 
Supplementary Table ST2. Analysis of DIGESTIF peptide release in human 
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sheet). 
Supplementary Table ST3. DIGESTIF and liver injury biomarker proteolysis in 
serum: label-free analysis of peptide release. 
Supplementary Table ST4. Complete data for multi-site assessment of 
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